958 related articles for article (PubMed ID: 18362664)
1. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
Kahook MY; Noecker RJ
Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops.
Kahook MY; Noecker R
Adv Ther; 2008 Aug; 25(8):743-51. PubMed ID: 18670744
[TBL] [Abstract][Full Text] [Related]
3. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
[TBL] [Abstract][Full Text] [Related]
4. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
6. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
7. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.
Liang H; Brignole-Baudouin F; Riancho L; Baudouin C
Ophthalmic Res; 2012; 48(2):89-101. PubMed ID: 22473057
[TBL] [Abstract][Full Text] [Related]
8. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost.
Baudouin C; Riancho L; Warnet JM; Brignole F
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4123-8. PubMed ID: 17724196
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.
Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
Curr Eye Res; 2011 Nov; 36(11):979-88. PubMed ID: 21999224
[TBL] [Abstract][Full Text] [Related]
10. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.
Liang H; Brignole-Baudouin F; Pauly A; Riancho L; Baudouin C
Adv Ther; 2011 Apr; 28(4):311-25. PubMed ID: 21424577
[TBL] [Abstract][Full Text] [Related]
11. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
12. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.
Kahook MY; Ammar DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):259-63. PubMed ID: 20565312
[TBL] [Abstract][Full Text] [Related]
13. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.
Pellinen P; Huhtala A; Tolonen A; Lokkila J; Mäenpää J; Uusitalo H
Curr Eye Res; 2012 Feb; 37(2):145-54. PubMed ID: 22049909
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system.
Ryan G; Fain JM; Lovelace C; Gelotte KM
BMC Ophthalmol; 2011 Apr; 11():8. PubMed ID: 21510881
[TBL] [Abstract][Full Text] [Related]
15. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects.
Stewart WC; Stewart JA; Jenkins JN; Jackson AL
J Glaucoma; 2003 Dec; 12(6):475-9. PubMed ID: 14646682
[TBL] [Abstract][Full Text] [Related]
16. Corneal and conjunctival changes caused by commonly used glaucoma medications.
Noecker RJ; Herrygers LA; Anwaruddin R
Cornea; 2004 Jul; 23(5):490-6. PubMed ID: 15220734
[TBL] [Abstract][Full Text] [Related]
17. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.
Whitson JT; Cavanagh HD; Lakshman N; Petroll WM
Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200
[TBL] [Abstract][Full Text] [Related]
18. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.
Guenoun JM; Baudouin C; Rat P; Pauly A; Warnet JM; Brignole-Baudouin F
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2444-50. PubMed ID: 15980234
[TBL] [Abstract][Full Text] [Related]
19. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
20. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2011 Jun; 28(6):501-10. PubMed ID: 21603985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
